(UroToday.com) The Plenary agenda of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting included a session, entitled “So Your Patient with Kidney or Bladder Cancer Responded to Immunotherapy: What’s Next?”. In this context, Dr. Tom Powles from Barts Cancer Institute discussed whether we can consider immunotherapy a truly curative approach for patients with advanced kidney and bladder cancer.